According to the good survival benefit of the TOGA [7] and RAINBOW [8] clinical trials, the NCCN (National Comprehensive Cancer Network) guidelines for gastric cancer in year 2015 recommends truastuzumab can be used as first-line chemotherapy for patients with human epidermal growth factor receptor-2 positive advanced gastric cancer, and points out that ramucirumab can be used for advanced gastric cancer patients after the failure of first-line chemotherapy. Here, ERBB2 is linked to gastric cancer.